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Abstract
HIV-1 is dependent upon cellular co-factors to mediate its replication cycle in CD4
+ T cells and macrophages, the two major
cell types infected by the virus in vivo. One critical co-factor is Cyclin T1, a subunit of a general RNA polymerase II elongation
factor known as P-TEFb. Cyclin T1 is targeted directly by the viral Tat protein to activate proviral transcription. Cyclin T1 is
up-regulated when resting CD4
+ T cells are activated and during macrophage differentiation or activation, conditions that
are also necessary for high levels of HIV-1 replication. Because Cyclin T1 is a subunit of a transcription factor, the up-
regulation of Cyclin T1 in these cells results in the induction of cellular genes, some of which might be HIV-1 co-factors.
Using shRNA depletions of Cyclin T1 and transcriptional profiling, we identified 54 cellular mRNAs that appear to be Cyclin
T1-dependent for their induction in activated CD4
+ T Jurkat T cells and during differentiation and activation of MM6 cells, a
human monocytic cell line. The promoters for these Cyclin T1-dependent genes (CTDGs) are over-represented in two
transcription factor binding sites, SREBP1 and ARP1. Notably, 10 of these CTDGs have been reported to be involved in HIV-1
replication, a significant over-representation of such genes when compared to randomly generated lists of 54 genes (p
value,0.00021). The results of siRNA depletion and dominant-negative protein experiments with two CTDGs identified
here, CDK11 and Casein kinase 1 gamma 1, suggest that these genes are involved either directly or indirectly in HIV-1
replication. It is likely that the 54 CTDGs identified here include novel HIV-1 co-factors. The presence of CTDGs in the protein
space that was available for HIV-1 to sample during its evolution and acquisition of Tat function may provide an explanation
for why CTDGs are enriched in viral co-factors.
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Introduction
The major targets of HIV-1 infection are CD4
+ T cells and
macrophages, as these two cell types express CD4 and CCR5 or
CXCR4, the receptor and co-receptor, respectively, for the viral
Envelope protein. However, the ability of CD4
+ T cells and
macrophages to support a productive HIV-1 infection depends
upon the physiological status of the cell. Fully resting CD4
+ T cells
are non-permissive for HIV-1 replication and must be activated to
support high levels of viral replication [1,2]. Monocytes are also
non-permissive for replication and must undergo a program of
macrophage differentiation to support HIV-1 infection [3]. In
resting CD4
+ T cells and monocytes, viral entry is not limiting for
infection, but rather a number of post-entry steps in the replication
cycle are defective, including: reverse transcription [1,4,5]; nuclear
import and integration of the viral cDNA [6,7]; nuclear export of
spliced viral mRNAs [8]; RNA polymerase II transcription of the
integrated provirus [9]. These defects in viral replication are likely,
in part, to be the result of limiting levels of cellular co-factors that
mediate the various steps in the viral life cycle. By expressing
adequate levels of all essential cellular co-factors, activated CD4
+
T cells and differentiated macrophages provide an optimal
environment for HIV-1 replication.
One essential co-factor for HIV-1 replication is Cyclin T1
which is targeted by the viral Tat protein to mediate RNA
polymerase II transcription of the integrated provirus (reviewed in
[10–13]). Cyclin T1 is one of several regulatory subunits of a set of
general elongation factors known collectively as P-TEFb [14,15].
The transcriptional elongation of most cellular genes is stimulated
by P-TEFb [16,17]. All P-TEFb complexes contain CDK9 as the
catalytic subunit, either the major 42 kDa protein or a minor
55 kDa protein that arises from an upstream transcriptional start
site [18]. P-TEFb complexes differ according to their regulatory
subunit, either Cyclin T1, two isoforms of Cyclin T2 termed
Cyclin T2a and T2b, or Cyclin K. A substantial portion of P-
TEFb is in a catalytically repressed form because of its association
with 7SK snRNA and the HEXIM1 or HEXIM2 proteins [19–
22]. The association of P-TEFb with 7SK snRNA and HEXIM
proteins may sequester P-TEFb in a complex from which
functional P-TEFb can be rapidly recruited to regulate RNA
polymerase II transcription [14,15].
The HIV-1 Tat protein specifically targets the Cyclin T1/P-
TEFb complex through a direct protein-protein interaction with
Cyclin T1 [23]. In the absence of the viral Tat protein, RNA
polymerase II initiates transcription within the viral 59 long
terminal repeat sequences, but the polymerase is non-processive
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limit elongation [11]. After expression of the Tat protein, Tat
binds to Cyclin T1/P-TEFb, and this protein complex then binds
to the TAR RNA element that forms at the 59 end of nascent viral
transcripts. The CDK9 subunit of P-TEFb can then phosphorylate
the carboxyl terminal domain of the large subunit of RNA
polymerase II and DSIF and NELF, thereby converting RNA
polymerase to a processive enzyme that is able to transcribe the
entire proviral genome.
Cyclin T1 protein expression is highly regulated in CD4
+ T cells
and macrophages, and this regulation correlates with permissibility
for HIV-1 replication. Cyclin T1 expression is low in resting CD4
+
T cells isolated from healthy donors, but upon T cell activation, it
is induced by a mechanism that appears to involve post-
transcriptional regulation [24,25]. Cyclin T1 expression is also
low in freshly isolated monocytes, and it is up-regulated by a post-
transcriptional mechanism within one to two days after the cells
are cultured under conditions that allow macrophage differenti-
ation [26]. However, after one to two weeks in culture, Cyclin T1
protein expression is shut-off in macrophages by proteasome-
mediated proteolysis. Treatment of macrophages with the
immunosuppressive cytokine IL-10 can accelerate this protea-
some-mediated shut-off of Cyclin T1 [27]. After it is shut-off in
late-differentiated macrophages, Cyclin T1 can be re-induced by
activation with agents such as LPS or by HIV-1 infection,
indicating that the induction of Cyclin T1 is a component of an
innate immune response in mature macrophages [28,29]. In
contrast to the regulated expression of Cyclin T1, the Cyclin T2
regulatory subunit of P-TEFb is expressed constitutively in resting
CD4
+ T cells and is not further induced by T cell activation [24].
Cyclin T2 is also expressed constitutively throughout macrophage
differentiation and it is not induced by macrophage activation
[29].
Given its role as the regulatory subunit of a general RNA
polymerase II elongation factor, the up-regulation of Cyclin T1
during T cell activation and macrophage differentiation or
activation suggests that Cyclin T1 is likely to be involved in the
induced transcription of many cellular genes in these cells. Our
recent study utilized shRNA depletions and DNA microarrays to
examine Cyclin T1-dependent genes (termed here CTDGs) in
MM6 cells, a monocytic cell line that can be induced to
differentiate into a macrophage-like phenotype by PMA treatment
[30]. We found that like primary monocytes, Cyclin T1 is
expressed at a low level in MM6 cells and it is up-regulated by a
post-transcriptional mechanism when differentiation is induced by
PMA. Also like primary monocytes/macrophages, the Cyclin T2
subunit of P-TEFb is expressed constitutively in MM6 cells and is
not up-regulated by PMA treatment. When Cyclin T1 expression
was depleted by shRNA, the expression of more than 20% of
PMA-induced genes in MM6 cells was inhibited, indicating that
the up-regulation of Cyclin T1 during monocyte differentiation is
required for the expression of a large portion of differentiation-
induced genes.
Our previous study identified CTDGs in PMA-treated MM6
cells, a setting that models the permissive environment for HIV-1
infection in differentiated macrophages [30]. In the present study,
we used shRNA depletions and DNA microarrays to identify
CTDGs in LPS-activated MM6 cells, another environment that
can be permissive for HIV-1 infection [31]. We also identified
CTDGs in activated Jurkat CD4
+ T cells, an additional
environment that is permissive for HIV-1 replication. We used
the DNA microarray data to identify a common set of 54 CTDGs
that are induced in activated CD4
+ T cell and differentiated and
activated macrophages. The promoters for these genes are of
interest, as their regulation is similar to that of the HIV-1 LTR:
Cyclin T1-dependent and inducible by T cell activation and
macrophage differentiation and activation. Remarkably, this set of
CTDGs is highly over-represented in proteins with a reported role
in HIV-1 replication. Our analysis of two genes in the list, CDK11
and Casein kinase1 gamma 1 (CSNK1G1), suggests that these two
genes also play a role in HIV-1 replication. It is therefore likely
that the list of CTDGs identified here contains novel HIV-1 co-
factors.
Results
Depletion of Cyclin T1 in MM6 and Jurkat T cells
To identify Cyclin T1-dependent genes (CTDGs), we used a
shRNA vector to deplete Cyclin T1 and evaluated the effects on
global gene expression with DNA microarrays. Genetic manipu-
lation of primary macrophages and CD4
+ T cells by shRNA
methodologies poses considerable technical challenges. Addition-
ally, variability between cells from different donors introduces a
complicating factor. Because of these technical issues, we carried
out Cyclin T1-depletion experiments in transformed cell lines. As
a model for activated CD4
+ T cells, we used Jurkat T cells, a cell
line derived from a human leukemia that has been widely used in
T cell activation studies [32,33]. As a model for monocytes/
macrophages, we used the Mono-Mac 6 (MM6) cell line. This cell
line is from a human leukemia and it exhibits characteristics of
mature monocytes, such as the expression of markers specific for
mature monocytes which are absent in the less mature human
promonocytic cells lines U937 and THP1 [34]. MM6 cells can be
induced to differentiate to a macrophage-like phenotype by PMA,
and they can be activated by LPS.
The shRNA lentiviral vector that we used expresses an eGFP
marker protein and does not express any lentiviral gene products
[35]. We constructed a lentiviral vector, termed shRNA-T1, which
expresses a shRNA that targets Cyclin T1 mRNA. We also
constructed a negative control shRNA vector, termed shRNA-
Con, which expresses a four-nucleotide mismatch to Cyclin T1
mRNA. We previously used these lentiviral vectors and DNA
microarrays to identify CTDGs in PMA-treated MM6 cells [30].
Without LPS activation, the basal level of expression of Cyclin
T1 in MM6 cells is low (Fig. 1A). LPS activation resulted in a
strong induction of Cyclin T1 in both parental MM6 cells and cells
transduced with the shRNA-Con vector. In contrast, Cyclin T1
expression was not induced in LPS-activated cells that were
transduced with the shRNA-T1 vector. Flow cytometry analysis
showed that .90% of cells in all transduced cultures expressed the
eGFP marker protein (data not shown). We observed in real-time
RT-PCR assays that Cyclin T1 mRNA levels were reduced
approximately four-fold in cells infected with the shRNA-T1
vector (data not shown).
Unlike MM6 cells, the basal level expression of Cyclin T1 in
Jurkat cells is high and it is not further induced by activation with
PMA+ ionomycin (Fig. 1B). We have observed a similar high basal
expression level of Cyclin T1 in the CD4
+ T cell lines CEM and
H9, and this basal level is not further induced by activation
(unpublished results). Cyclin T1 expression was not affected in
Jurkat cells transduced with the shRNA-Con vector. In contrast,
Cyclin T1 expression was significantly reduced in untreated and
activated Jurkat cells that were transduced with the shRNA-T1
vector. Flow cytometry analysis indicated that .90% of cells in all
transduced cultures expressed the eGFP marker protein (data not
shown). Using real-time RT-PCR assays, we also observed that the
mRNA levels of Cyclin T1 were reduced approximately four-fold
in shRNA-T1 transduced cells relative to shRNA-Con transduced
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in Figure 1 demonstrates that the shRNA-T1 vector is effective in
depleting Cyclin T1 protein expression and this system can be
used to identify CTDGs in LPS-treated MM6 cells and PMA/
ionomycin-treated Jurkat cells.
Transcriptional profiling: validation and analysis of
microarray data
To examine how the depletion of Cyclin T1 affects global gene
expression, we utilized Affymetrix human genome U133 Plus 2.0
DNA arrays representing about 18,953 unique (non-redundant)
transcripts. DNA microarrays were used to analyze two indepen-
dent biological replicate experiments of MM6 cells treated with
LPS and Jurkat cells treated with PMA/ionomycin. DNA
microarrays were also used to analyze three biological replicates
with PMA treated MM6 cells. To verify that the microarray data
are reliable, we performed real-time PCR assays for several
mRNAs whose levels in microarrays were affected by the various
treatments. For all mRNAs assayed, the PCR-based assays were in
accordance with the microarray data, indicating that the
microarray data are in general reliable (Fig. S1). We performed
a similar PCR assay validation of the microarray data in Cyclin
T1-depletions of PMA-treated MM6 cells [30]. Additionally,
dendograms were generated based upon the expression measures
of all probes sets on the Affymetrix array (Figs. S2, S3). These
dendrograms demonstrated that RNA preparations from cells
subjected to the various treatments partitioned into the expected
groups, further indicating that the microarray data are reliable.
The primary microarray data was deposited in the NCBI GEO
database (see Materials and Methods).
Cellular genes repressed by Cyclin T1 depletions in both
activated MM6 and Jurkat cells
We used the transcriptional profiling data to identify the genes
that were repressed .1.5-fold (p-value,0.05) by Cyclin T1
depletions relative to the shRNA-Con vector in PMA/ionomy-
cin-treated Jurkat cells, PMA-treated MM6 cells, and LPS-treated
MM6 cells. There were 644 such genes in Jurkat cells, 965 in
PMA-treated MM6 cells and 778 in LPS-treated MM6 cells
(Fig. 2). The intersection of these three gene sets contain the 54
genes listed in Table 1. We performed a gene ontology analysis to
determine if this gene set was over-represented in any biological
processes. A number of processes involved in intracellular
transport and localizations of proteins were found to be over-
represented (Fig. S4). Six genes in the list are related to these
biological processes: Adaptor-related protein complex 1, mu 1
subunit (AP1M1); FYN binding protein (FYB-120/130); Pituitary
tumor-transforming 1 interacting protein (PTTG1IP); RAB1A;
RAB7L1; VPS24 (also called CHMP3). Given this over-represen-
tation of genes involved in protein transport and localization, it is
intriguing that these processes are involved in HIV-1 Gag
trafficking and virion budding [36,37].
SEBP1 and ARP1 binding sites are over-represented in
CTDGs
The CTDGs listed in Table 1 are Cyclin T1-dependent and
inducible by T cell activation, macrophage differentiation, and
macrophage activation. Because this regulation is similar to that of
the HIV-1 LTR subjected to the same treatments in these cell
types, we were interested in identifying transcription factor binding
sites in the promoters of the CTDGs that are over-represented
relative to the expected number in 54 random promoters. We
therefore used the TOUCAN program [38] to examine
transcription factor binding (TFBS) sites. We extracted 1.5 kb
upstream of the first exon of the 54 genes, as it has been estimated
Figure 1. A) MM6 cells: non-infected or MM6 cells infected at an
m.o.i. of five with the indicated lentiviral vector were cultured for five
days. Cells were then treated with LPS for 24 hours as indicated. Cell
extracts were prepared and immunoblots performed to measure levels
of Cyclin T1, CDK9, and b-actin. B) Jurkat cells: non-infected or Jurkat
cells infected at an m.o.i. of five with the indicated lentiviral vector were
cultured for five days. Cells were then treated with PMA+ ionomycin for
24 hours as indicated. Cell extracts were prepared to measure
expression of Cyclin T1, CDK9, and b-actin.
doi:10.1371/journal.pone.0003146.g001
Figure 2. CTDGs. The Venn diagram represents the number of genes
whose mRNAs were reduced .1.5-fold (p value,0.05) by Cyclin T1
depletions. Cyclin T1-dependency was observed for 965 of the PMA-
inducible genes in MM6 cells, 778 of the LPS-inducible genes in MM6
cells, and 644 of the PMA/ionomycin-inducible genes in Jurkat cells. The
number of genes in intersections of gene sets is indicated.
doi:10.1371/journal.pone.0003146.g002
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1,500 bp of the transcription start site [39]. Using a database of
transcription factors and their binding sites TRANSFAC (7.0
public, Vertebrates), TFBS in the promoters were predicted
against a background model obtained from Eukaryotic Promoter
Database. TFBSs that were statistically over-represented were
identified by comparison of the frequency of each transcription
factor in our data set against their background frequency.
We found that binding sites for two transcription factors,
SREBP1 and ARP1 (also called COUP-TFII or NR2F2), were
over-represented in the promoters for the 54 genes. As shown in
Figure 3, a total of 17 SREBP1 binding sites and 19 ARP1 binding
sites were found in the set of 54 promoters. Both SREBP1 and
ARP1 are over-represented over their expected frequencies, with p
values,0.00013 and ,0.0003, respectively. SREBP1 (sterol
regulatory element binding transcription factor 1) positively
regulates genes involved in fatty acid and cholesterol synthesis
[40]. ARP1 is involved in the regulation of genes involved in
metabolism of glucose, cholesterol and xenobiotics [41]. No other
transcription factor binding sites were found to be statistically
over-represented, including those for Sp1, NF-kB, and TFIID.
These are notable absences as the HIV-1 LTR contains two highly
conserved NF-kB sites, three highly conserved Sp1 binding sites,
and an essential TATA element.
CTDGs are enriched in factors involved in HIV-1
replication
We examined our list of CTDGs for published links to HIV-
1 replication. Notably, 10 proteins were found to have a link to
HIV-1 (indicated by bold italics in Table 1): 1) SKP2 is
involved in Tat function through the ubiquitylation of the
CDK9 subunit of P-TEFb [42]; 2) AP1m1 is utilized by the
HIV-1 Nef protein to down-regulate CD4 and MHC I [43,44];
3) deoxyhypusine synthase is involved in Rev function through
an unusual protein modification of its co-factor eIF-5A [45,46];
4) Actin related protein 2/3 complex, subunit 1A (ARPC1A) is
involved in an HIV-1 pre-integration step and in viral budding
[47,48]; 5) CARD6 is involved in NF-kB activation [49]; 6)
LAMP1 co-localizes with the HIV-1 Gag protein in macro-
phages [50]; 7) granulin is involved in Tat function through an
association with Cyclin T1 [51]; 8) VPS24 (CHMP3) is involved
in viral budding [52]; 9,10) MHC class I-related (MR1) and
Ankyrin repeat domain 6 (ANKRD6) act prior to viral budding
[48].
After finding that 10 genes in our set of 54 have a link to HIV-1
replication, we were interested to determine if this number is
significantly greater than in sets of 54 genes chosen at random. To
generate legitimate random lists, we selected only genes present in
Table 1.
Gene Name (Gene ID) Gene Name (Gene ID)
1. Golgi autoantigen, golgi subfamily a, 7 (GOLGA7) 28. Glycolipid transfer protein (GLTP)
2. Nucleosome assembly protein 1-like 5 (NAP1L5) 29. Rho GTPase activating protein 30 (ARHGAP30)
3. NSFL1 (p97) cofactor (p47) (NSFL1C) 30. Pyruvate dehydrogenase kinase, isozyme 3 (PDK3)
4. S-phase kinase-associated protein 2 (p45) (SKP2) 31. Chromosome X open reading frame 40A (Cxorf40A)
5. ATPase, Class VI, type 11A (ATP11A) 32. Niemann-Pick disease, type C2 (NPC2)
6. Adaptor-related protein complex 1, mu 1 subunit (AP1M1) 33. Iduronate 2-sulfatase (Hunter syndrome) (IDS)
7. Deoxyhypusine synthase (DHPS) 34. Eukaryotic translation initiation factor 2C, 4 (EIF2C4)
8. Casein kinase 1, gamma 1 (CSNK1G1) 35. Pituitary tumor-transforming 1 interacting protein (PTTG1IP)
9. Hypothetical protein LOC144438 (LOC144438) 36. Adenosine deaminase, RNA-specific, B1 (RED1 homolog rat) (ADARB1)
10. MHC, class I-related (MR1) 37. KIAA1458 protein (KIAA1458)
11. RAB7, member RAS oncogene family-like 1 (RAB7L1) 38. Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) (DAB2)
12. Actin related protein 2/3 complex, subunit 1A, 41kDa (ARPC1A) 39. Potassium large conductance calcium-activated channel, subfamily M, beta member 1
(KCNMB1)
13. Lipase A, lysosomal acid, cholesterol esterase (LIPA) 40. CTTNBP2 N-terminal like (CTTNBP2NL)
14. Coiled-coil domain containing 32 (CCD32) 41. Neuroblastoma RAS viral (v-ras) homolog (NRAS)
15. Dihydropyrimidinase-like 2 (DPYSL2) 42. Lysosomal-associated membrane protein 1 (LAMP1)
16. CDK11: Cell division cycle 2-like 2 (PITSLRE proteins) (CDCL2L2) 43. Chromosome 1 open reading frame 121 (C1orf21)
17. Caspase recruitment domain family, member 6 (CARD6) 44. Transmembrane protein 107 (TMEM107)
18. Cytochrome b reductase 1 (CYBRD1) 45. Granulin (GRN)
19. Phosphatase and actin regulator 4 (PHACTR4) 46. Cathepsin B (CTSB)
20. 1-acylglycerol-3-phosphate O-acyltransferase 3 (AGPAT3) 47. Transmembrane protein 106A (TMEM106A)
21. Pyridoxal (pyridoxine, vitamin B6) kinase (PDXK) 48. LSM12 homolog (S. cerevisiae) (LSM12)
22. MYC associated factor X (MAX) 49. Ankyrin repeat domain 6 (ANKRD6)
23. Tubulin, beta 2B (TUBB2B) 50. Vacuolar protein sorting 24 homolog (S. cerevisiae) (VPS24)
24. RAB1A, member RAS oncogene family (RAB1A) 51. Hepatitis A virus cellular receptor 2 (HAVCR2)
25. DEAD box polypeptide 18 (DDX18) 52. Ras association (RalGDS/AF-6) domain family 2 (RASSF2)
26. DAZ associated protein 2 (DAZAP2) 53. Integrin beta 4 binding protein (ITGB4BP)
27. FYN binding protein (FYB-120/130) (FYB) 54. Membrane protein, palmitoylated 5 (MAGUK p55 subfamily member 5) (MPP5)
doi:10.1371/journal.pone.0003146.t001
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in both MM6 cells and Jurkat T cells (see Materials and Methods).
We generated seven sets of 54 random genes and analyzed each
for published links with HIV-1 replication. We found that these
sets had from one to four genes (average 2.4) with a reported link
to HIV. Thus, the gene set shown in Table 1 is significantly over-
represented in links to HIV-1 replication relative to randomly
generated sets of 54 genes (p value,0.00021). This finding
indicates that the CTDGs listed in Table 1 are highly likely to
contain novel HIV-1 co-factors.
CDK11 depletion affects Tat function
We investigated two genes in our 54 gene list for a role in HIV-1
replication. Our attention was drawn to CDK11, as an RNAi
screen in Drosophila observed that CDK11 and CDK9 are linked in
a genetic network that regulates the Hedgehog pathway [53].
Because CDK9 is a component of the Tat co-factor P-TEFb, we
asked whether a genetic link between these two kinases exists in
Tat function.
CDK11 is a ubiquitously expressed member of the CDK family.
There is considerable complexity in human CDK11, as it is
Figure 3. SREBP1 binding sites in CTDGs. The 1.5 kb sequences upstream of the first exon of genes are indicated (both strands). Predicted
binding sites on both DNA strands are indicated.
doi:10.1371/journal.pone.0003146.g003
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duplication – Cdc2L1 and Cdc2L2 (Cell division control 2 Like).
Differential splicing from these two genes generate more than 20
distinct CDK11 mRNAs that encode two related proteins,
CDK11
p110 and CDK11
p58. During apoptosis, a third CDK11
p46 isoform is generated by caspase cleavage of the p110 and p58
proteins. The available data indicate that the p110, p58, and p46
CDK11 proteins are involved in mRNA production, mitosis, and
apoptosis, respectively [54].
To deplete CDK11 globally, we used siRNAs that target a
conserved RNA sequence present in all transcripts from the two
CDK11 genes. As shown in Figure 4A, these siRNAs are effective
in depleting the CDK11 p110 protein, the isoform involved in
mRNA production. The CDK11 depletion also resulted in an
approximate 40% decrease in expression of CDK9 and HEXIM1,
but not b-actin, CDK8, and CDK7 (not shown). The reduction in
CDK9 and HEXIM1, although relatively modest, is specific and
reproducible and suggests that CDK11 may somehow regulate the
expression of these proteins. The effect of the depletion on
HEXIM1 is quite notable, as about 50% of P-TEFb in HeLa cells
is associated in a complex with HEXIM1 (or the minor HEXIM2)
protein and a small nuclear RNA known as 7SK snRNA. P-TEFb
is catalytically inactive when associated with HEXIM1/7SK. The
association of P-TEFb with HEXIM1/7SK may sequester excess
P-TEFb in a complex from which functional P-TEFb can be
rapidly recruited to regulated RNA polymerase II transcription
[14,15]. Using propidium iodide staining and flow cytometry, we
observed that there is no apoptosis or cytotoxicity resulting from
the CDK11-depletion prior to 72 hr post-transfection with the
CDK11 siRNAs. Thus, the two-fold reduction in CDK9 and
HEXIM1 protein levels is unlikely to be the result of cytotoxicity
or apoptosis. We also observed that shRNA depletions of CDK9
did not affect the expression level of CDK11 (data not shown),
suggesting that CDK9 may be downstream of CDK11.
We examined whether the CDK11-depletion had an effect on
expression of anHIV-1 Luciferasereporter virus. This virus contains
Luciferase in place of the Nef gene and contains a deletion of
Envelope; it is pseudotyped with the VSV G glycoprotein to allow
entry.Weconstructed a control HIV-1 Luciferasereporter virus that
has an inactive Tat protein; Luciferase expression from this reporter
virus is therefore largely Tat-independent [27]. A pool of HeLa cells
engineered to express Renilla Luciferase from the DHFR promoter
(an internal control that is P-TEFb-independent [30]) was infected
with either the Tat
+ or Tat
2 Luciferase reporter virus. At 48 hours
post-infection with reporter viruses, siRNAs against CDK11,
negative control siRNAs, or a positive control of siRNAs against
Cyclin T1 were transfected into cells. Cell extracts were then
prepared 48 hours after siRNA transfections and Luciferase
expression was measured.
As shown in Figure 4B, Luciferase expression from the Tat+
virus was reduced ,40% by siRNAs against Cyclin T1 relative to
the control siRNAs. The siRNAs against CDK11 reduced
expression ,50% relative to the control siRNAs, a slightly more
severe reduction than the Cyclin T1 siRNAs. Relative to the
control, Luciferase expression from the Tat- virus was reduced
only ,10% and ,20% by siRNAs against Cyclin T1 and
CDK11, respectively. These data indicate that Tat function is
especially sensitive to depletion of either Cyclin T1 or CDK11.
Thus, like the Hedgehog pathway in Drosophila, CDK9 (P-TEFb)
and CDK11 appear to be functionally linked for Tat function.
Figure 4. CDK11 depletion reduces protein expression of CDK9 and HEXIM1 and Tat transactivation of HIV-1 provirus. A. HeLa cells
were transfected with siRNAs against CDK11 siRNA or control siRNAs. Cells were harvested 72 h post-transfection and cell lysates were analyzed for
expression of CDK11, CDK9, HEXIM1, and CDK8 by immunoblots. B. HeLa cells were infected with a lentiviral DHFR-Renilla Luciferase virus with GFP
marker. Cells sorted for GFP were then infected with either HIV-1 NL4-3-firefly Luciferase virus (wild type) or with HIV-1 NL4-3 firefly Luciferase virus
encoding a mutant Tat (Tat2) for 48 h. Cultures were transfected with the indicated siRNAs. Cell extracts were prepared 48 h post-transfection and
assayed for Luciferase expression. Results are presented as the ratio of firefly to Renilla Luciferase expression.
doi:10.1371/journal.pone.0003146.g004
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Tat function through effects on CDK9 expression levels or the
processing of HIV-1 transcripts.
Casein kinase 1gamma1 (CSNK1G1) reduces virion
infectivity
One of the genes in our gene set, Casein kinase 1 gamma
(CSNK1G1), is a plasma membrane-bound member of the casein
kinase 1 (CK1) family. Although CSNK1G1 has not been
extensively studied, the Xenopus protein has been found to be
involved in Wnt signaling [55]. Given the intriguing localization of
this kinase at the plasma membrane, the site of retroviral assembly
and budding, we carried out a preliminary analysis of the role of
CSNK1G1 in HIV-1 replication.
In an experimental strategy illustrated in Figure 5, cultures of
293T cells were transfected with siRNAs against CSNK1G1 (or
control siRNAs), and then transfected with a HIV-1 pNL4-3-Luc
proviral plasmid (deleted for Envelope) and a plasmid that
expresses the VSV G glycoprotein to allow production of
infectious pseudotyped viruses. This HIV-1 provirus contains
Luciferase in place of Nef. Culture supernatants were collected
48 hours post-transfection with the proviral and VSV G plasmids.
The amount of p24 in culture supernatants was reduced ,20% in
the CSKN1G1-depleted cells relative to the control siRNA cells
(Fig. 5). Equal volumes of the supernatants from 293T cells
containing the HIV-1 reporter viruses were used to infect HeLa
cells, and Luciferase expression was measured 48 hours later.
Luciferase expression was then normalized to the amount of p24
in the 293T supernatant inoculum (Fig. 5). The data indicate that
the infectivity of viruses produced in the CSNK1G1-depleted cells
was reduced five-fold relative to that produced in the control
siRNA cells.
To begin to explore mechanisms whereby CSNK1G1 may be
involved in virion infectivity, we examined the effects on Gag
Figure 5. CSNK1G1 depletions. As illustrated, 293T cells were transfected with either control siRNAs or siRNAs against CSNK1G1. One day later,
cells were co-transfected with the pNL4-3-Luc and pVSV-G plasmids for virus production. Supernatants were collected 48 hours later and p24 levels
were measured by an ELISA assay. Infectivity of supernatants containing reporter the NL-4-3-Luc reporter viruses were measured by infecting HeLa
cells with equal volume of supernatants, and Luciferase expression was measured 48 hours post-infection. Luciferase expression was normalized to
the amount of p24 in the input supernatants.
doi:10.1371/journal.pone.0003146.g005
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CSNK1G1 protein. The dn-CSNK1G1 contains a point mutation
(K73R) in the ATPase domain that inactivates catalytic function
[55]. Cultures of 293T cells were transfected with 0.5 or 1.0 mg
of expression plasmids for wild type CSNK1G1, dn-CSNK1G1,
or parental vector and one day later cultures were transfected with
a pNL4.3-GFP proviral reporter plasmid. One day after
transfection of the proviral reporter plasmid, cell lysates were
prepared and processing of cell-associated Gag was examined in
an immunoblot (Fig. 6). In cultures transfected with the dn-
CSNK1G1 plasmids, processing of Gag to p24 as quantified by
the ratio of p24 to the 55 kDa Gag precursor was significantly
reduced relative to cultures co-transfected with the wild type
CSNK1G1 plasmid or parental vector. This observation suggests
that perturbation of CSKN1G1 function by the dominant negative
protein can inhibit Gag processing. The data shown in Figures 5
and 6 indicate that CSKN1G1 appears to be a co-factor involved
in virion infectivity.
Discussion
CTDGs are likely to contain novel HIV-1 co-factors
Using a shRNA vector to deplete Cyclin T1, we identified a
common set of 54 Cyclin T1-dependent genes (CTDGs) in PMA/
ionomycin-activated Jurkat T cells, PMA-treated MM6 cells, and
LPS-treated MM6 cells. Because Cyclin T1 is a general RNA
polymerase II transcription factor, its depletion will affect genes
that are directly regulated by Cyclin T1. The expression levels of
some additional mRNAs are likely to be dependent upon genes
that are direct targets of Cyclin T1. Our shRNA depletion of
Cyclin T1 therefore likely resulted in down-regulation of some
mRNAs through indirect mechanisms. Additionally, as we used a
single shRNA against Cyclin T1 in this study, we cannot exclude
the possibility that some of the CTDGs identified here are the
results of off-target effects of the shRNA. Nevertheless, the
CTDGs are highly enriched in SEBP1 and ARP1 binding sites
in their promoters (p values,0.00013 and ,0.0003) and in genes
related to HIV-1 replication (p value,0.00021), strongly suggest-
ing that our CTDG gene set has biological relevance. Until further
characterization, it will remain possible that some of these 54
genes are false-positives for their dependency on Cyclin T1.
The 54 CTDGs identified in this study include 10 genes with a
reported link to HIV-1 replication: ARPC1A acts at a pre-
integration step and at viral budding [47,48]; CARD6 is involved
in NF-kB activation [56]; SKP2 and granulin are involved in Tat
function [57,58]; deoyhypusine synthase is involved in Rev
function [59]; AP1M1 is involved in Nef function [60,61];
LAMP-1 appears to be involved in Gag function [50]; VPS24 is
involved in viral budding [62]; ANKRD6 and MR1 act prior to
viral budding [48]. As discussed in Results, the identification of 10
of 54 genes with a link to HIV-1 replication is a highly significant
over-representation (p value,0.00021) over the expected number
(2.4) in randomly generated lists of 54 genes that are expressed in
both Jurkat and MM6 cells. It is probable that future genome wide
siRNA screens will identify additional genes involved in HIV-1
replication. If this is the case, random lists of 54 genes are likely to
contain by chance more than 2.4 genes involved in HIV-1
replication. However, if these new co-factors are identified, it is
possible that they will include some of the CTDGs identified here
and our gene list may retain its over-representation of genes linked
to HIV-1 replication.
An additional CTDG in our list is probably linked to HIV-1
replication – RAB1A (Table 1, gene 24) interacts with RUSC2
which was identified as an HIV-1 co-factor in a recent large scale
siRNA screen [48]. We have also provided evidence here that both
CDK11 and CSKN1G1 are linked to HIV-1 replication. We
conclude that this over-representation of genes with relevance to
HIV-1 strongly suggests that our list of CTDGs contains a number
of novel HIV-1 co-factors. Future studies using siRNA depletions
will determine which of the CTDGs are important in the HIV-1
life cycle.
Why are CTDGs enriched in HIV-1 co-factors?
During its course of evolution into an infectious agent, HIV-1
acquired Cyclin T1 to mediate Tat stimulation of RNA
polymerase II elongation of the provirus. Cyclin T1 is a general
transcription factor, and the induced expression of Cyclin T1 in
activated CD4
+ T cells and macrophage drives the expression of
many cellular genes. The protein products of many of these
CTDGs were therefore always present in infected cells as the virus
acquired Cyclin T1 as a co-factor and optimized its replication
cycle during evolution. This enrichment of CTDGs in the protein
space that was available for HIV-1 to sample during its evolution
in CD4+ T cells and macrophages may explain why our list of 54
CTDGs is over-represented in viral co-factors. Our method to
identify CTDGs in CD4+ T cells and macrophages was not
exhaustive and it seems likely that a number of additional CTDGs
serve as viral co-factors.
Binding sites for SREBP1 and ARP1 are enriched in
promoters for CTDGs
The HIV-1 LTR and the CTDGs identified here have similar
patterns of regulation: Cyclin T1-dependent and inducible by T
cell activation and macrophage differentiation or activation.
Because the HIV-1 LTR contains two conserved NF-kB sites,
three conserved Sp1 sites, and a conserved TATA element [63], it
is notable that binding sites for these factors are not over-
represented in promoters for the CTDGs. Mutational analyses of
the HIV-1 LTR have demonstrated that this set of transcription
factor binding sites is especially suited to confer a high response to
the Cyclin T1/p-TEFb complex when it is recruited to the viral
LTR via Tat and TAR RNA [64–67]. However, we found here
Figure 6. Effects of over-expression of wild type and dn-
CSNK1G1 proteins on Gag processing. Cultures of 293T cells were
transfected with 0.5 or 1.0 mg wild type CSNK1G1, dn-CSNK1G1, or
parental vector (pcDNA 3.0) expression plasmids. One day later, cultures
were transfected with pNL4-3-GFP proviral reporter plasmid and cell
extracts were prepared one day later. Gag processing in virions
associated with cells were examined in an immunoblot using a p24
monoclonal antibody. The ratio of p24 to the 55 kDa Gag precursor is
indicated at the bottom of the immunoblot and it was and it was
quantified by scanning the film and software analysis.
doi:10.1371/journal.pone.0003146.g006
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their up-regulation in activated CD4
+ T cells and macrophages do
not possess the combination of transcription factor binding sites
that is found in the HIV-1 LTR. Thus, the combination of binding
sites for NF- kB, Sp1, and the TATA is not essential, and may not
be common, for CTDGs in activated CD4+ T cells and
macrophages. It should be noted, however, that our study did
not investigate whether the set of CTDGs are stimulated directly,
rather than indirectly, by Cyclin T1.
Binding sites for the transcription factors SREBP1 and ARP1
are over-represented (p value,0.00013 and ,0.0003, respectively)
in the CTDGs in this study, as the promoters for 21 of 54 genes
contain at least one predicted binding site for these factors (Fig. 3).
SREBP1 is a membrane-associated protein that is activated by
limited proteolysis and transported to the nucleus where it
regulates genes involved in lipid and cholesterol metabolism
[68]. ARP1 (also termed COUP-TFII) regulates metabolic
homeostasis and can act as both an activator or repressor of
target genes [69]. The 21 CTDGs whose promoters contain
binding sites for SREBP1 and/or ARP1 may be involved in
regulating metabolic conditions in both CD4
+ T cells and
macrophages, and this may be important for HIV-1 replication.
This raises the possibility that variation in metabolism between
HIV-infected individuals may be a contributing factor to
differences in the course of disease.
Potential for new therapeutic targets
Our initial experiments to examine a role of CSNK1G1 in
HIV-1 replication suggests that it functions to enhance virion
infectivity, as a siRNA depletion appeared to reduce infectivity
(Fig. 5) and a dn-CSNK1G1 protein inhibited Gag processing
(Fig. 6). Additional work is required to elucidate mechanisms
whereby CSNK1G1 affects virion infectivity and whether this host
protein has the possibility to serve as a target for anti-viral
therapeutics. Although several CTDGs identified in this study play
important roles in HIV-1 infection, in most cases the encoded
proteins are unlikely to be targeted by HIV-1 proteins through
direct protein-protein interactions. Many of these cellular proteins
may regulate general cellular processes, and other proteins
involved in these processes could be the direct targets of viral
proteins. For example, Tat function is sensitive to the depletion of
CDK11 (Fig. 4). Rather than having a direct effect on Tat
function, CDK11 may regulate the level of CDK9 protein
expression or the processing of HIV-1 transcripts, and because
P-TEFb function and splicing are linked [15], the depletion of
CDK11 may have an especially inhibitory effect on viral
transcripts activated by Tat. HIV-1 co-factors that regulate
general cellular processes are unlikely to be feasible therapeutics
targets, as the actions of small molecules that interfere with their
function are likely to be cytotoxic.
However, a number of cellular co-factors that mediate HIV-1
replication are feasible candidates for anti-viral drugs. Some co-
factors in the 54 CTDGs identified here, and in the 273 factors
identified in the recent large-scale siRNA screen [48], are likely to
exist in multiprotein complexes that are targeted directly by viral
proteins. The future characterization of these complexes and their
role in the HIV-1 life cycle can identify proteins that are direct and
essential targets of viral proteins. Such proteins are feasible
therapeutic targets, as small molecules can be developed that
disrupt protein-protein interactions [70]. Indeed, the recently
licensed drug Maraviroc is a small molecule that blocks HIV-1
entry by binding to CCR5 on the surface of cells and thereby
prevents a productive interaction between CCR5 and the HIV-1
Envelope protein [71].
Materials and Methods
Cell culture and reagents
Mono-Mac-6 cells (MM6) were obtained from Dr. Jorge Benach
(State University of New York at Stony Brook). MM6 cells were
maintained in RPMI 1640 medium (Invitrogen) supplemented
with 10% heat-inactivated fetal bovine serum (FBS, Hyclone),
antibiotics, non-essential amino acids (Invitrogen), l-glutamine
(Invitrogen), and OPI media supplement (Sigma) containing
0.15 mg of oxalacetate, 0.5 g of pyruvate and 8.2 mg of bovine
insulin. Jurkat cells were purchased from ATCC and maintained
in RPMI 1640 medium supplemented with 10% FBS and
antibiotics. For LPS treatment of MM6 cells, cultures were treated
at a final concentration of 1 ng/ml lipopolysacchride (LPS,
Sigma); for PMA treatment of MM6 cells, cultures were treated
at a final concentration of 10 ng/ml phorbol 12-myristate 13-
acetate (PMA, Sigma). For PMA+ ionomycin treatment of Jurkat
cells, cultures cells treated at a final concentration of 1 ng/ml
PMA (Sigma) and 1 mM ionomycin. HeLa cells and 293T cells
were maintained in 10% FBS and antibiotics.
Cell Extracts and Immunoblots
Cell extracts were prepared by incubating cells in lysis buffer
(50 mM Tris, 120 mM NaCl, 0.5% NP-40) containing protease
inhibitors (2 mg/ml aprotinin, 1 mg/ml leupeptin, 2.5 mM
phenylmethylsulfonyl fluoride) as described previously [72].
Protein concentrations were determined by a Bio-Rad protein
assay, and 20 mg of total protein was loaded onto sodium dodecyl
sulfate-9% polyacrylamide gels. The procedure for immunoblots
using enhanced chemiluminescence for detection has been
described previously [73]. Antibody to b-actin was purchased
from Sigma, and other antibodies were purchased from Santa
Cruz Biotechnology.
ShRNAs, siRNAs, and lentiviral vector production
The target sequences used for this study were: shRNA-CycT1,
GCAGCGTCTTAACGTCTCA; shRNA-Control (MM), GCT-
ATAGCTGTTCTAGTTC; CDK11, CAUGAGUAUUUCCG-
CGAGA; CSNK1G1, GACCGAACAUUUACUUUGAUU.
The siRNAs were purchased from Dharmacon. Construction of
the viral vector has been described previously [30]. The FG12
lentiviral vector is a self-inactivated lentiviral vector carrying an
eGFP expression-cassette; the vector does not encode any viral
gene products [35].
Stocks of the FG12 lentiviral vectors pseudotyped with vesicular
stomatitis virus (VSV)-G were produced by calcium phosphate-
mediated transient transfection of HEK-293T cells. Briefly, HEK-
293T cells were cultured in DMEM (GIBCO Invitrogen)
containing 10% FBS (HyClone), and antibiotics. The cells were
cotransfected with 5 ug of: shRNA vector plasmid, the HIV-1
lentiviral packaging constructs pRSV/REV and pMDLg/pRRE,
and the VSV-G expression plasmid pHCMV-G. Virus stocks were
collected from the culture supernatants on days two post-
transfection and were titered on HEK-293T cells based on GFP
expression. MM6 cells (2610
5/ml) were transduced at a
multiplicity of infection (m.o.i.) of five in the presence of 5 ng/
ml polybrene (Sigma).
Microarray analysis
The primary microarray data was deposited at the NCBI GEO
data base (accession numbers GSE10232, GSE10233, GSE10234).
Microarray analysis was performed by the Baylor Microarray
Core Facility (Baylor College of Medicine, Houston, TX 77030,
USA). Detailed protocols can be found at the website: http://
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ed using the Qiagen RNeasy kit according to the manufacturer’s
protocol and RNA quality was determined using an Agilent 2100
Bioanalyzer. RNA was reverse transcribed to generate cDNA and
transcribed using T7 RNA polymerase and biotinylated ribonu-
cleotides to generate labeled cRNA. Fragmented cRNA was
hybridized to U133 plus 2.0 human gene chips (Affymetrix)
containing nearly 55,000 probe sets representing over 18,953
transcripts. Following washing and staining, the arrays were
scanned using an Affymetrix Gene Chip Scanner 3000. For all
experiments, the 59/39 ratios of GAPDH ranged between 0.85 and
0.91. Comparisons of matched control and were performed for
each of three independent experiments. Microarray data was
analyzed with online software from Genesifter.
To generate random lists of genes whose mRNAs are expressed
in both MM6 and Jurkat cells, microarray data were normalized
by calculation of the GC Robust Multi-Array Average (GCRMA);
random gene lists were then generated from genes that were
expressed in both cell lines at log2 expression levels .3. To
determine if genes in lists contain a published link to HIV-1
replication, gene names (and aliases) were searched in the NCBI
Pub Med Database for a link to HIV. Genes were also analyzed in
the NCBI HIV-1 Human Protein Interaction Database.
Real-time RT-PCR analysis
Quantitative real-time RT-PCR was performed using the Bio-
Rad MyIQ single color detection system. Cellular RNA was used
to perform cDNA synthesis using the iScript cDNA synthesis kit
(Bio-Rad). Briefly, 1 mg of RNA was reverse transcribed in a 20-ml
reaction volume using the manufacturer’s protocol. PCR reactions
were performed using 3 ml of cDNA in a 50 ml reaction containing
25 mlo f2 6 iQ SYBR Green Supermix (Bio-Rad) and 200 nM
final concentration of each primer. PCR reactions were carried
out in 96-well format using a Bio-Rad iCycler with a 3 min hot
start followed by 40 cycles of 15 s at 95uC, 1 min annealing and
amplification at 55uC. Analysis was performed using the MyIQ
software program (Bio-Rad). The threshold crossing (Ct) value for
each reaction was determined and the fold-change (DDCt value)
was calculated with the following formulas using GAPDH as a
reference control:
Primers for quantitative PCR were designed using Beacon
Designer 2.0 (Premier Biosoft). All primer pairs produced single
amplification products as determined by gel electrophoresis as well
as melt-curve analysis using the MyIQ system. Primers used:




GAPDH (forward) CGCCAGCCGAGCCACATC, GAPDH
(reverse) AATCCGTTGACTCCGACCTTCAC; HAVCR2





CACCGCCTTC; PTGS1 (forward): TTATGGCTGCTGGG-
CTGAGTG, PTGS1 (reverse): GCTTCCTGTCCTTCCTGC-
TCTG; TDO2(forward): AACCTCCGTGCTTCTCAGACAG,
SPP1(forward): CAGGAGGAGGCAGAGCACAG; VEGF (for-
ward): GCGTGCGAGCAGCGAAAG, VEGF (reverse): GGCG-
GTGTCTGTCTGTCTGTC, VPS24 (forward): AAAGCCCA-
GCCACTGTCTCAC, VPS24 (reverse): CCACCGCACC-
CAGCCAAG.
HIV-1 reporter virus experiments and Gag processing
experiments
For reporter virus experiments in CDK11 depletion experi-
ments, a HeLa cell culture was infected with lentiviral DHFR-
Renilla Luciferase virus containing an eGFP marker protein.
Infected cells were sorted for eGFP expression, and were then
infected with either HIV-1 NL4-3-Firefly Luciferase virus (wild
type Tat) or with HIV-1 NL4-3 Firefly Luciferase virus encoding a
mutant Tat [27]. The infected cultures were then transfected with
50 pmol of siRNAs against CDK11 or Control siRNAs. Cell
extracts were prepared 48 h post-transfection and assayed for
firefly and renilla Luciferase expression.
For siRNA depletions of CSNK1G1, 293T cells in 12-well
culture dishes were transfected with 120 pmol of either siRNAs
against CSNK1G1 or negative control siRNAs (Cyclin T1
mismatch control siRNAs). One day after siRNA transfections,
cells were co-transfected with HIV-1 proviral plasmid pNL4-3-
Luciferase and a plasmid expressing the VSV G glycoprotein
(pVSV-G). Two days after plasmid co-transfections supernatants
were collected and p24 amounts were measured by ELISA
(Beckman-Coulter). HIV-1 infectivity in supernatants was mea-
sured by infecting HeLa cells with equal volumes of virion-
containing supernatants, Luciferase expression was measured two
days post-infection, and Luciferase expression was normalized to
p24 amounts in supernatants.
The Quikchange site-directed mutagenesis kit (Stratagene) was
used to introduce the K73R mutation into a CSNK1G1 cDNA.
Wild-type and mutant CSNK1G1 cDNA were cloned into a C-
terminal HA-tagged pcDNA 3.0 plasmid (Invitrogen). To examine
Gag processing, 293T cells were transfected with Lipofectamine
2000 (Invitrogen) at Day 0 with the CSNK1G1 constructs or
empty vector (pcDNA3.0). On day 1, cells were transfected with
pNL4-3.GFP proviral reporter. On day 2, supernatants were
centrifuged at 1,0006g for 10 minutes, and lysed with 0.5%
Triton X-100 in PBS; cells were lysed with 16Cell Culture Lysis
Reagent (Promega). Equal volumes of supernatant and 40 ug of
cell lysate protein were heated at 95uC for 10 minutes, run on
10% polyacrylamide gels, and transferred to nitrocellulose
membranes. Blocking with 5% non-fat dried milk in TBS-T
(50 mm Tris pH 8.0, 200 mM NaCl, 0.2% Tween-20) was
performed for 1 hour, and primary antibody (p24 monoclonal,
NIH AIDS Research and Reagent Program;183-H12-5C from
Dr. Bruce Chesebro and Kathy Wehrly) binding was done
overnight in the same solution at a dilution of 1:1000. Horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz Biotech-
nology) were bound for 1 hour in 0.5% non-fat dried milk in TBS-
T and SuperSignal West Pico Substrate (Pierce) was used for
detection. Bands were quantified by scanning the film with a
Molecular Dynamics Densitometer and quantifying bands with
Image Quant 5.2 software (Molecular Dynamics).
Supporting Information
Figure S1 A. LPS-treated MM6 cells. MM6 cells were infected
with the shRNA-T1 or shRNA-Con (Cyclin T1 mismatch)
lentiviral vector for five days, treated with LPS for 24 hours,
and total RNA was isolated. Quantitative real-time RT-PCR
assays were used to measure the expression levels of the indicated
mRNAs. The fold-change value represents the change in mRNA
levels in cells relative to parental MM6 cells after normalization to
GAPDH levels. Fold-change values after LPS treatment as
measured in microarray hybridizations were: MARCKS, 0.30;
TDO2, 0.06; SPP1, 0.45; HLA-DR, 0.50; CX3CR1, 0.12. B.
PMA/ionomycin-treated Jurkat cells. Jurkat cells were infected
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lentiviral vector for five days, treated with PMA/ionomycin for
24 hours, and total RNA was isolated. Quantitative real-time RT-
PCR assays were used to measure the expression levels of the
indicated mRNAs. The fold-change value represents the change in
mRNA levels in shRNA-T1-infected cells relative to shRNA-Con-
infected cells after normalization to GAPDH levels. Fold-change
values after PMA-ionomycin treatment as measured in microarray
hybridizations were: APOBEC3F, 0.26; PTGS1, 0.20; CHMP4,
0.32; VEGF, 0.22; HAVCR2, 0.26.
Found at: doi:10.1371/journal.pone.0003146.s001 (0.06 MB TIF)
Figure S2 PMA-treated and LPS-treated MM6 cells have
distinct RNA expression profiles. A dendrogram was constructed
with the data from all probe sets for all 15 microarrays used to
analyze parental, PMA-treated, or LPS-treated MM6 cells
(uninfected, shRNA-T1-infected, shRNA-Con (Cyclin T1 mis-
match)-infected). The Pearson Correlation distance was calculated
to represent the expression differences between the microarrays.
The leaves of the tree represent each of the 15 microarrays used in
this study. The branches denote the relative distances between the
samples. Branch joints near the leaves of the tree represent high
similarity, while deeper joints represent less similarity.
Found at: doi:10.1371/journal.pone.0003146.s002 (0.06 MB TIF)
Figure S3 PMA/ionomycin-treated Jurkat cells depleted for
Cyclin T1 have a distinct gene profile from PMA/ionomycin-
treated control Jurkat cells. A dendrogram was constructed based
on the data from all probe sets for all 8 microarrays used with
Jurkat cells. The Pearson Correlation distance was calculated to
represent the expression differences between the microarrays. The
leaves of the tree represent each of the 8 arrays used. The branches
denote the relative distances between the samples.
Found at: doi:10.1371/journal.pone.0003146.s003 (0.04 MB TIF)
Figure S4 Gene Ontology Analysis of CTDGs. A GO content
analysis of the gene list in Table 1 was performed by tabulating the
gene list against the GO structure. The color of each GO term
corresponds to its adjusted P-value, with color intensity indicated
by color scaling.
Found at: doi:10.1371/journal.pone.0003146.s004 (0.06 MB TIF)
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